AcelRx Pharmaceuticals has begun the final phase of its three studies on a new patient-controlled analgesia system, ARX-01, the Sufentanil NanoTab PCA System, according to PharmaBiz.com.
This phase is a double-blind, placebo controlled efficacy and safety trial in adults following hip or knee replacement surgery.
The third study will test the new product on 400 patients, randomized 3:1, and will be conducted at 45 academic and community hospitals in the country.
The ARX-01 system is designed to address the limitations of current PCA with morphine by offering a high therapeutic index opioid with low instance of drug-related side effects.
More Articles on Anesthesia:
Anesthesiology: Blood Clotting Algorithms Can Reduce Transfusion Requirements, Cut Hospital Costs
Endo Health Solutions Reports Above Expectations $785M Revenue Increase
New Anesthetic Agents Could Outperform Current Drugs
This phase is a double-blind, placebo controlled efficacy and safety trial in adults following hip or knee replacement surgery.
The third study will test the new product on 400 patients, randomized 3:1, and will be conducted at 45 academic and community hospitals in the country.
The ARX-01 system is designed to address the limitations of current PCA with morphine by offering a high therapeutic index opioid with low instance of drug-related side effects.
More Articles on Anesthesia:
Anesthesiology: Blood Clotting Algorithms Can Reduce Transfusion Requirements, Cut Hospital Costs
Endo Health Solutions Reports Above Expectations $785M Revenue Increase
New Anesthetic Agents Could Outperform Current Drugs